Article

Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Advanced Neuroendocrine Tumours (NETs) in a Limited Resource Environment

2020-11-20

Abstract excerpt

<title>Abstract</title> <p>BackgroundWe decided to evaluate the clinical efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177-DOTATATE in patients with neuroendocrine tumors (NETs).MethodsSixteen patients with pathologically verified NETs including eight females and eight males were enrolled in this study. Before PRRT for evaluation of somatostatin receptor expressing, the patients underwe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 39ce2913-3c56-5ce4-9439-dfa9fee2acd1
DOI: 10.21203/rs.3.rs-111380/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Advanced Neuroendocrine Tumours (NETs) in a Limited Resource EnvironmentDOI 10.21203/rs.3.rs-111380/v1Read

Identification of Genes Related to 68Ga-DOTATATE Organ Distribution in Homo SapiensSemantic proximity Read

MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy.Semantic proximity Read

Profiling proteomic responses in small intestinal neuroendocrine tumor GOT1 after [177Lu]Lu-DOTATATE therapySemantic proximity Read

Somatostatin Receptor Based Imaging and Radionuclide TherapySemantic proximity Read

Molecular Imaging for Response Assessment of Neuroendocrine Tumors (NET)Semantic proximity Read

New Developments in Peptide Receptor Radionuclide TherapySemantic proximity Read

Understanding the Radiobiological Mechanisms Induced by 177Lu-DOTATATE in Comparison to External Beam Radiation TherapySemantic proximity Read

Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?Semantic proximity Read

DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivoSemantic proximity Read

Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy.Semantic proximity Read

A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing-tumor as a potential target of peptide receptor imaging and therapySemantic proximity Read

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).Semantic proximity Read